In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] In development GID-TA10893 Expected publication date: TBC ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England. People ...

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of ...

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer Technology appraisal guidance TA885 Published: 03 May 2023 ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...